Eesti - eesti - Ravimiamet

teva pharma b.v. - bikalutamiid - õhukese polümeerikattega tablett - 50mg 30tk; 50mg 60tk; 50mg 100tk; 50mg 40tk; 50mg 50tk; 50mg 28tk; 50mg 84tk; 50mg 90tk; 50mg 56tk

Eesti - eesti - Ravimiamet

actavis group ptc ehf. - bikalutamiid - õhukese polümeerikattega tablett - 50mg 100tk; 50mg 5tk; 50mg 140tk; 50mg 84tk; 50mg 40tk; 50mg 7tk; 50mg 14tk; 50mg 50tk; 50mg 280tk; 50mg 200tk; 50mg 98tk; 50mg 28tk; 50mg 80tk; 50mg 30tk

Eesti - eesti - Ravimiamet

actavis group ptc ehf. - bikalutamiid - õhukese polümeerikattega tablett - 150mg 40tk; 150mg 140tk; 150mg 7tk; 150mg 280tk; 150mg 200tk; 150mg 90tk; 150mg 28tk; 150mg 5tk; 150mg 98tk

Eesti - eesti - Ravimiamet

grindeks as - bikalutamiid - õhukese polümeerikattega tablett - 50mg 14tk; 50mg 60tk; 50mg 28tk; 50mg 30tk; 50mg 10tk; 50mg 50tk

Eesti - eesti - Ravimiamet

fresenius kabi polska sp. z o.o. - bikalutamiid - õhukese polümeerikattega tablett - 50mg 50tk; 50mg 90tk; 50mg 14tk; 50mg 30tk; 50mg 60tk; 50mg 56tk; 50mg 100tk; 50mg 28tk

Eesti - eesti - Ravimiamet

accord healthcare b.v. - bikalutamiid - õhukese polümeerikattega tablett - 50mg 100tk; 50mg 30tk; 50mg 98tk; 50mg 20tk; 50mg 14tk; 50mg 84tk; 50mg 90tk; 50mg 28tk; 50mg 60tk

Eesti - eesti - Ravimiamet

teva pharma b.v. - bikalutamiid - õhukese polümeerikattega tablett - 150mg 30tk; 150mg 84tk; 150mg 56tk; 150mg 40tk; 150mg 20tk; 150mg 100tk; 150mg 28tk; 150mg 90tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - aprepitant - kõvakapsel - 80mg/125mg 2tk / 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cobicistat, atazanavir - hiv-nakkused - viirusevastased ravimid süsteemseks kasutamiseks - evotaz is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4. 4 ja 5.

Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan pharmaceuticals limited - darunaviiri - hiv-nakkused - viirusevastased ravimid süsteemseks kasutamiseks - darunavir, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv-1) infection (see section 4. darunavir mylan 75 mg, 150 mg, 300 mg and 600 mg tablets may be used to provide suitable dose regimens (see section 4. 2):ravi hiv-1 nakkuse retroviirusevastast ravi (art)-kogenud täiskasvanud patsientidele, sealhulgas neid, mis on väga eeltöödeldud. ravi hiv-1 nakkuse pediaatrilised patsiendid alates vanusest 3 aastat ja vähemalt 15 kg kehakaalu kohta. otsustades ravi alustada darunavir co-manustatakse koos väikeses annuses ritonaviiri, tuleks hoolikalt kaaluda ravi ajalugu konkreetse patsiendi ja mustreid mutatsioonid on seotud erinevate mõjurite. genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir (see sections 4. 2, 4. 4 ja 5. darunavir co-manustatakse koos väikeses annuses ritonaviir on näidustatud kombinatsioonis teiste viirusevastase ravimitega ravi patsientidel, kellel on inimese immuunpuudulikkuse viiruse (hiv-1) nakkus.  darunavir co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg) (see section 4.  darunavir mylan 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are: antiretroviral therapy (art)-naïve (see section 4.  art-experienced with no darunavir resistance associated mutations (drv-rams) and who have plasma hiv-1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 10⁶/l. otsustades ravi alustada darunavir sellisel kunsti-kogenud patsientidel, genotypic katsetamine peaks juhendi kasutamine darunavir (vt lõigud 4. 2, 4. 3, 4. 4 ja 5.